Kyverna receives FDA fast track status for KYV-101 to treat multiple sclerosis
The fast track status follows the recent Investigational New Drug (IND) clearance for the candidate for use in…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
22 Jan 24
The fast track status follows the recent Investigational New Drug (IND) clearance for the candidate for use in…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
19 Jan 24
EVO756 is a highly selective, potent small molecule antagonist of mas-related G-protein coupled receptor X2, designed to block…
19 Jan 24
Founded in 2019, Summit Biosciences is an intranasal drug-delivery contract development and manufacturing organisation serving the unit dose…
19 Jan 24
Both firms will work to understand rare tumours in patients treated with immune checkpoint inhibitors by characterising their…
19 Jan 24
Zokinvy is indicated for Hutchinson-Gilford progeria syndrome (HGPS) and processing deficient progeroid laminopathy (PDPL), two ultra-rare paediatric diseases…
19 Jan 24
Lipocine retains all rights for territories outside the United States and Canada, and all non-TRT rights globally
18 Jan 24
In conjunction with the acquisition of PPS, Alcami is enhancing its presence in central North Carolina's pharmaceutical storage…
18 Jan 24
Xenetic has signed the research funding agreement and material transfer agreement with UVA to obtain an exclusive license…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
18 Jan 24
Along with istaroxime, the agreement licences Windtree’s preclinical next-generation SERCA2a activators, called dual mechanism SERCA2a activators
18 Jan 24
The US FDA has cleared Amplia's Investigational New Drug (IND) Application for a clinical trial of narmafotinib in…